Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma

Cancer

Volumn 103, Issue 5, 2005, Pages 931-942

  Fukata, Satoshi ^a   Inoue, Keiji ^a   Kamada, Masayuki ^a   Kawada, Chiaki ^a   Furihata, Mutsuo ^a   Ohtsuki, Yuji ^a   Shuin, Taro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Clear cell renal cell carcinoma; Metastasis; Renal cell carcinoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; UVOMORULIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CAPILLARY DENSITY; CLEAR CELL CARCINOMA; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

AGED; CADHERINS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERLEUKIN-8; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13944262883     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20887     Document Type: Article

References (63)

1. Jemal A, Murray T, Samuel A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. Cancer J Clin. 2003;53:5-26.
2. Mai KT, Landry DC, Robertson SJ, et al. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract. 2001;197:671-675.
3. Guinan PD, Vogelzang NJ, Fremgen AM, et al. Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol. 1995; 153:901-903.
4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
5. Bretheau D, Lechevallier E, de FM, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76:2543-2549.
6. Ljungberg B, Larsson P, Stenling R, Roos G. Flow cytometric deoxyribonucleic acid analysis in stage I renal cell carcinoma. J Urol. 1991;146:697-699.
7. Grignon DJ, Ayala AG, el-Naggar A, et al. Renal cell carcinoma. A clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer. 1989;64:2133-2140.
8. Pound CR, Partin AW, Epstein JI, Simons JW, Marshall FF. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology. 1993;42: 243-248.
9. Morell QL, Clar BF, Fenollosa EB, Perez BM, Martinez LA, Llombart BA. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res. 1998;18:677-682.
10. Haitel A, Wiener HG, Blaschitz U, Marberger M, Susani M. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers. Cancer. 1999;85:1593-1598.
11. Onda H, Yasuda M, Serizawa A, Osamura RY, Kawamura N. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. Oncol Rep. 1999;6:1039-1043.
12. Rioux LN, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501-505.
13. Strohmeyer D. Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res. 1999;19: 1557-1561.
14. Fujimoto K, Ichimori Y, Kakizoe T, et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun. 1991;180: 386-392.
15. Nanus DM, Schmitz DB, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993;85: 1597-1599.
16. Duensing S, Grosse J, Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res. 1995;15:2331-2333.
17. Wechsel HW, Bichler KH, Feil G, Loeser W, Lahme S, Petri E. Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res. 1999;19:1537-1540.
18. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237.
19. Nicol D, Hii SI, Walsh M, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 1997;157:1482-1486.
20. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 2000;163:343-347.
21. Paradis V, Lagha NB, Zeimoura L, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch. 2001;436:351-356.
22. Konig B, Steinbach F, Janocha B, et al. The differential expression of proinflammatory cytokines 1L-6, 1L-8 and TNF-alpha in renal cell carcinoma. Anticancer Res. 1999;19: 1519-1524.
23. Miyake H, Hara I, Yoshimura K, et al. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res. 1996;56:2440-2445.
24. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol. 1998;160: 1914-1918.
25. Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer. 2000;85:801-804.
26. Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer. 1995;71:376-379.
27. Fischer C, Georg C, Kraus S, Terpe HJ, Luedecke G, Weidner W. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res. 1999;19:1513-1517.
28. Kuniyasu H, Ellis LM, Evans DB, et al. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res. 1999;5:25-33.
29. Herbst RS, Yano S, Kuniyasu H, et al. Differential expression of E-cadherin and type FV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res. 2000;6:790-797.
30. Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type FV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res. 2000;6:2295-2308.
31. Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000;6: 4866-4873.
32. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001;158:735-743.
33. Rogelj S, Weinberg RA, Fanning P, Magsbrun M. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature. 1988;331:173-175.
34. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3:211-220.
35. Inoue K, Slaton JW, Kim SJ, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000;60:2290-2299.
36. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer [In Process Citation]. Clin Cancer Res. 2000;6:2104-2119.
37. Greene GF, Kitadai Y, Pettaway CA, von EA, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol. 1997;150:1571-1582.
38. Kitadai Y, Bucana CD, Ellis LM, Anzai H, Tahara E, Fidler IJ. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am J Pathol. 1995;147:1238-1247.
39. Radinsky R, Bucana CD, Ellis LM, et al. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res. 1993;53:937-943.
40. Bucana CD, Radinsky R, Dong Z, Sanchez R, Brigati DJ, Fidler IJ. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdrl in mouse colon carcinoma cells. J Histochem Cytochem. 1993;41:499-506.
41. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques. 1992;13:434-443.
42. Schlingemann RO, Rietveld FJ, de Waal RM, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest. 1990;62:690-696.
43. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
44. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994;54:2852-2855.
45. Sampson JR, Patel A, Mee AD. Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family. J Med Genet. 1995;32:848-850.
46. Nakopoulou L, Vouriakou C, Papaliodi E, Lazaris AC, Stefanaski K, Michalopoulos G. Immunodetection of c-met-oncogene's protein product in renal cell neoplasia. Pathol Res Pract. 1997;193:299-304.
47. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy [abstract]. Cancer J Sci Am. 1995;1:131.
48. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology. 1998;55:575-581.
49. Vermeulen PB, Verhoeven D, Hubens G., et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol. 1995;6:59-64.
50. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
51. Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology. 1998;51:693-696.
52. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol. 1997;80:401-404.
53. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology. 1995;46:27-30.
54. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 1995;2:156-160.
55. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987-993.
56. Ikeguchi M, Makino M, Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol. 2001;77:201-207.
57. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789-4796.
58. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986;46:1-7.
59. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 1992;7:120-125.
60. Liotta LA, Steuer SW, Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990;1:99-106.
61. Levy AT, Cioce V, Sobel ME, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 1991;51:439-444.
62. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113-3119.
63. Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82:166-168.